9.9% annualized 3-year return is not impressive given 0.32 beta—a stock delivering bond-like risk for stock-like returns is a discount, not a premium

• 9.9% annualized 3-year return
• 0.32 beta
• S&P 500 long-run total return ~10%/year
• CL underperformed S&P by 16.5 percentage points over 6 months (+1.9% vs +18.4%)
• Polymarket shows 97% probability of no Fed cuts in 2026
• 10-year yield is rising, not falling

↩ rebuts: “Bull's 'mean-reversion setup' is impressive performance”

21x forward P/E is elevated for CL's profile when compared to relevant defensive universe and does not reflect the company's operational challenges

• Utilities trade at 15-18x forward
• Mature consumer staples median: 18-20x forward
• CL is at the top of the consumer staples range
• P&G trades at ~25x with higher organic growth and better category leadership
• 3-5% revenue growth (decelerating in mature markets)
• Negative book equity
• Current ratio of 1.026 (razor-thin)
• $919M goodwill impairment in recent past
• 75-80% EM exposure in volatile currencies
• If macro deteriorates, 21x compresses to 18x, then 16x before EPS normalizes

↩ rebuts: “Bull's assertion that 21x forward P/E is 'fair' or 'cheap'”

The 200-day SMA failed on a closing basis—this is a confirmed technical breakdown, not a 'gift'

• CL closed at $86.06 on 2026-09-25
• 200-day SMA at $87.60
• Stock closed $1.54 below the 200 SMA
• 10 EMA flipped from support in early August to resistance (regime change)
• MACD line crossed below signal line on ~2026-09-21 (fresh bearish cross)
• 09-25 bounce was on light volume (yellow flag for institutional sponsorship)
• ATR fell during sell-off—'final flush' is one of two possible outcomes per bull's own report

↩ rebuts: “Bull's characterization of 200-day SMA holding as a 'gift'”

The $1B divestiture of Softsoap/Irish Spring/Speed Stick is being shopped by Goldman Sachs because these brands are losing at retail—it's a confession of failure, not a Buffett-style cleanup

• Goldman Sachs is shopping the assets
• Haleon is winning shelf space at Walmart and Target
• Mass-market personal care category has compressed into a price war
• Divestitures take months to close with no guarantee on price
• No guarantee proceeds go to accretive M&A vs. buybacks at compressing multiple

↩ rebuts: “Bull's framing of the divestiture as a 'Buffett-style portfolio cleanup'”

Haleon and P&G are winning structural shelf space at the highest-velocity US retail channels, and CL's gross margin expansion is being offset by SG&A spend to defend share it is still losing

• Haleon winning shelf at Walmart and Target (25-30% of mass-market personal care volume)
• CL must either match commercial terms (margin compression) or lose shelf (revenue compression)
• P&G regained #1 in China baby care with double-digit organic growth
• DTC brands (Quip, Burst) taking millennial/Gen Z wallet share
• Gross margin expanded 140bps YoY but operating margin compressed from 21.14% to 18.95%
• SG&A ballooned from $1.96B to $2.13B
• CL is paying up for advertising to defend share it is still losing

↩ rebuts: “Bull's claim that CL has pricing power and that competitive pressure is 'overblown'”

Macro 'higher for longer' rate regime actively threatens CL: it compresses dividend multiples mechanically, makes the 2.46% yield uncompetitive vs. risk-free alternatives, strengthens the dollar (hurting EM revenue), and triggers consumer trade-down behavior

• 10-year yields rising mechanically compress dividend stock multiples
• CL 2.46% yield is inferior to 4-5% Treasury with same risk profile
• Capital doesn't rotate into CL when T-bills become competitive
• Rising yields historically strengthen the dollar, hurting 75-80% non-US revenue
• Diesel/freight costs hit gross margin directly for globally exposed name
• Zandi warning: higher rates damage real economy, triggering consumer trade-down to private label
• CL's premiumization strategy runs straight into a volume headwind

↩ rebuts: “Bull's characterization of macro as a tailwind”

CL's 2.46% dividend yield is 250 basis points below risk-free T-bill/money market yields—the opportunity cost of holding CL is enormous

• CL dividend yield: 2.46%
• Money market / T-bill yield: ~5%
• Spread: CL yields 250bps less than risk-free cash
• HOLD earns less than a money market fund
• Modern equity returns driven by narrative capital; CL has none
• Reddit silence means no catalyst for multiple expansion

↩ rebuts: “Bull's framing of HOLD as 'waiting to add' when waiting earns more in cash”

Operating leverage is breaking the wrong direction—SG&A discipline is failing, and Hill's Pet Nutrition (largest US growth driver) faces intensifying competition from Nestlé Purina and Mars

• Operating margin compressed 219bps (21.14% to 18.95%)
• SG&A grew from $1.96B to $2.13B
• Premium pet food showing recent weakness
• Nestlé Purina and Mars intensifying competition for Hill's Pet Nutrition
• If Hill's flattens, CL loses primary organic US growth lever
• Tariff risk on raw materials and finished goods for globally exposed name is asymmetric
• 2025 goodwill write-down precedent signals brand values may not be durable

↩ rebuts: “Bull's implicit assumption that CL is a 'high-quality compounder' with operating leverage”

Probability-weighted return is -0.4% to +1.5%—not a BUY setup; scenarios show asymmetry is roughly 1:1 to 1:2 against the bull

• Bull scenario (20% probability): +10.5% return to $95
• Base scenario (45% probability): +1.1% return to $87 avg
• Bear scenario (25% probability): -9.4% return to $78
• Tail scenario (10% probability): -16.3% return to $72
• Probability-weighted return: -0.4% to +1.5%
• Downside targets: $83 (3.5% down), $78 (9.4% down), $74 from multiple compression (14% down)
• Upside target requires flawless execution of divestiture, EM currency stability, margin defense, and defensive rotation—heroic assumptions for zero operational momentum

↩ rebuts: “Bull's 3:1 risk/reward calculation”